{"id":103652,"date":"2019-10-15T09:28:52","date_gmt":"2019-10-15T13:28:52","guid":{"rendered":"https:\/\/www.ucf.edu\/news\/?p=103652"},"modified":"2020-02-12T11:25:04","modified_gmt":"2020-02-12T16:25:04","slug":"new-treatment-shows-promise-for-drug-resistant-breast-cancer-cells","status":"publish","type":"post","link":"https:\/\/www.ucf.edu\/news\/new-treatment-shows-promise-for-drug-resistant-breast-cancer-cells\/","title":{"rendered":"New Treatment Shows Promise For Drug Resistant Breast Cancer Cells"},"content":{"rendered":"
UCF cancer researcher Jihe Zhao has been awarded a $100,000 grant from the Breast Cancer Research Foundation to develop a therapy for cancer that has become resistant to the most commonly used drug to fight the disease.<\/p>\n
One in eight women will develop breast cancer and it is the leading killer amongst women with cancer in the United States.<\/p>\n
Breast cancer tumors often have too much of a protein called HER2 present on the cell surface and high levels of the protein causes tumor growth. Hercepti\u00adn (also known as trastuzumab) \u2013 an effective HER2-inhibiting drug \u2014 was developed to treat HER2-positive breast cancer patients. However, even among early stages, more than 25 percent of patients developed resistance to the drug within as little as a year of treatment resulting in tumor relapse. Worse still, up to 75 percent of the late stage tumors resist Herceptin even if it is given in combination with chemotherapy.<\/p>\n
Hercepti\u00adn is still a top choice for treating HER2-positive breast cancer patients but drug resistance is a top concern. Despite the advancement in anti-breast cancer therapies, there is no effective treatment for drug-resistant tumor relapses.<\/p>\n
Working with Sudipta Seal, professor of materials science and engineering<\/a> and director of the Nanoscience Technology Center<\/a> at UCF, Zhao found that preliminary experiments using cell culture have shown that Herceptin, if used in combination with cerium oxide nanoparticles, can kill Herceptin-resistant breast cancer cells very effectively. \u201cThis is very promising because the normal tissue-friendly cerium oxide nanoparticles may help Herceptin to eliminate the drug-resistant breast cancer tumors in vivo,\u201d\u00a0says Zhao.<\/p>\n Zhao hopes that his research will lead to clinical trials in the future to help eradicate Herceptin-resistant breast cancer cells and save lives.<\/p>\n","protected":false},"excerpt":{"rendered":" A UCF researcher will help develop a way to treat drug-resistant breast cancer patients.<\/p>\n","protected":false},"author":57,"featured_media":103653,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"lazy_load_responsive_images_disabled":false,"footnotes":"","_links_to":"","_links_to_target":"","_wp_rev_ctl_limit":""},"categories":[12],"tags":[979,18082,2270,2297,3279,15761,14916],"tu_author":[],"class_list":["post-103652","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-college-of-medicine","tag-health","tag-impact","tag-innovation","tag-nanoscience-technology-center","tag-pegasus-briefs","tag-research"],"yoast_head":"\n